Zydus Lifesciences

西德斯生命科学

on Monday said it has received approval from US health regulator USFDA to market a generic antifungal medication to treat dandruff,

周一表示，已获得美国健康监管机构USFDA的批准，可销售一款用于治疗头皮屑的仿制抗真菌药物，

fungal infections

真菌感染

, and other skin conditions. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture

，以及其他皮肤状况。公司已获得美国食品药品监督管理局（USFDA）的最终批准以进行生产

Ketoconazole Shampoo

酮康唑洗发水

, 2 pc, it said in a statement.

，共2件，声明中说道。

Ketoconazole shampoo is an antifungal medication used to treat dandruff, fungal infections, and other skin conditions.

酮康唑洗发水是一种抗真菌药物，用于治疗头皮屑、真菌感染和其他皮肤状况。

The product will be produced at the Zydus Group's

该产品将在Zydus集团的工厂生产。

topical manufacturing

局部制造

site at Changodar,

位置在昌戈达尔，

Ahmedabad

艾哈迈达巴德

.

。

As per IQVIA MAT January 2025 data, Ketoconazole shampoo had annual sales of USD 68.89 mn in the US.

根据IQVIA MAT 2025年1月的数据，酮康唑洗发水在美国的年销售额为6889万美元。

Shares of Zydus Lifesciences were trading 0.22 per cent up at Rs 903.10 apiece on BSE.

Zydus Lifesciences 的股票在 BSE 上涨 0.22%，每股交易价格为 903.10 卢比。

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)